PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biol Pharm Bull. Author manuscript; available in PMC Jul 15, 2013.
Published in final edited form as:
PMCID: PMC3711093
NIHMSID: NIHMS489769
Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 on the Transepithelial Transport of a Mercaptoacetamide-Based Histone-Deacetylase Inhibitor in Caco-2 Cells
Zacharoula Konsoula and Mira Jung*
Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center; Washington D.C. 20057- 1482, U.S.A.
*To whom correspondence should be addressed. jungm/at/georgetown.edu
Oral bioavailability is one of the important criteria for development of a drug-lead candidate. In this study, the absorptive characteristics and the efflux mechanism of a mercaptoacetamide-based histone deacetyalse (HDAC) inhibitor, coded as W2, were investigated using Caco-2 cells. The transport of W2 was asymmetric as indicated by 1.85 fold higher basolateral to apical (BL to AP) than apical to basolateral (AP to BL) flux. Such asymmetry was associated with multidrug resistance associated protein 1 (MRP1) and P-glycoprotein (P-gp), as evidenced by specific inhibition of these proteins. In the presence of verapamil and cyclosporin A, potent inhibitors of P-gp, the apparent permeability ratio (Papp BL to AP/Papp AP to BL) of W2 was decreased from 1.85 to 0.73 and 1.03, respectively, and the absorption from apical to basolateral side was enhanced from 13.3±0.2 × 10–6 cm/s to 17.3±0.12 × 10–6 cm/s and 19±0.3 × 10–6 cm/s, respectively. Upon addition of quinidine, a mixed P-gp and MRP1 inhibitor, the permeation of W2 from the apical side was significantly increased (Papp 17.1±0.32 × 10–6 cm/s) while the efllux was inhibited (Papp 21.3±0.19×10–6 cm/s). Furthermore, the influence of the MRP1 inhibitors, indomethacin and N-benzyl-indomethacin (NBI) was evaluated. NBI treatment attenuated the basolateral to apical flux of W2 (Papp 20.3±0.1 × 10–6 cm/s), whereas this effect was completely abrogated by indomethacin (Papp 11±0.4 × 10–6 cm/s). The results suggest that P-gp and MRP1 transporters are capable of mediating the efflux of W2 and might play a significant role in its oral absorption.
Keywords: histone deacetylase inhibitor, mercaptoacetamide, P-glycoprotein, multidrug resistance associated protein 1, caco-2 cell line
It is well documented that histone acetyltransferases (HATs) and histone deacetylases (HDACs) are important regulators of chromatin and play central role as transcriptional modifiers.1) Abnormal HAT or HDAC activity has been reported in several cancers.2) Inhibition of HDACs often results in cellular differentiation, growth arrest and apoptosis in a broad spectrum of tumor cells and in vivo.3) Several HDAC inhibitors such as vorinostat (suberoylanilide hydroxamic acid),4) MS-275,5) phenylbutyrate6) and depsipeptide7) have shown potent anti-tumor activities and are currently in Phase I and II clinical trials. Recently, vorinostat was approved for the treatment of cutaneous T-cell lymphoma (CTCL).
One of the most important reasons for chemotherapy resistance is the increased expression of the ATP-binding cassette (ABC) transport proteins which lower intracellular anti-cancer drug concentrations in an energy-dependent manner. The ABC family includes among others the multidrug resistance associated proteins (MRP), P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). In the intestinal epithelium several ABC transporters are localized in the apical membrane of the enterocyte, including P-gp, MRP2 and BCRP, catalyzing the efflux of compounds to the intestinal luminal side.8) The MRP1, MRP3 and MRP5 transport proteins are located on the basolateral membrane of the enterocyte, thus catalyzing the efflux of compounds to the serosal side.9)
The human colonic adenocarcinoma Caco-2 cell line is the most widely employed in vitro model that mimics the absorptive properties of the intestinal epithelium.10) The Caco-2 cell model has been used for evaluating the intestinal transport mechanism of metals, nutrients and drugs.11,12) These cells spontaneously differentiate in culture into polarized monolayers and exhibit morphological features such as tight junctions, microvilli, and brush border enzymes found in enterocytes.13,14) Additionally, due to the fact that drug efflux proteins are functionally expressed in Caco-2 membranes,15) these cells have been employed extensively for studying P-gp or MRP mediated transport.16,17)
6-[(2-Mercaptoacetyl)amino-N-8-quinolinyl-hexamide] (6MAQH) coded as W2 (Fig. 1) is a mercaptoacetamide-based HDAC inhibitor with potent anti-tumor activities in a broad spectrum of solid and hematologic malignancies.18) Previous studies conducted in our laboratory have shown that the secretary permeation (basolateral to apical) of W2 was higher than the absorptive (apical to basolateral).19) The asymmetry observed between absorption and secretion fluxes can be attributed to an active transporter, effluxing W2 towards the apical compartment. Such transporters have already been described, as they are related to the resistance of various tissues to xenobiotics.20) Hence, it was of interest to explore both P-gp and MRP inhibition in this study in order to elncidate the W2 transport through tight cell monolayers. We hypothesized that inhibition of intestinal P-gp might decrease the efflux of W2 from the blood into the intestinal lumen, thereby, increasing the bioavailability of the compound. The P-gp inhibitors (verapamil, cyclosporin A),21,22) the mixed inhibitor of P-gp/MRP1 (quinidine) as well as the MRP1 inhibitors (indomethacin, N-benzyl-indomethacin)23,24) have been selected in order to distinguish the possible carriers implicated in the transport of W2.
Fig. 1
Fig. 1
Chemical Structure of 6-[(2-Mercaptoacetyl)amino-N-8-quinolinyl-hexamide] (6MAQH) Coded as W2
Materials
Caco-2 cells were obtained from the Tissue Culture Shared Resources of the Lombardi Comprehensive Cancer Center. Dulbecco's Modified Eagle Medium (DMEM) containing d-glucose (4.5 g/l) and l-glutamine, Hanks’ balanced salt solution (HBSS), 0.05% trypsin-EDTA, phosphate buffered saline (PBS, pH 7.4), penicillin–streptomycin (10000 U/ml—10000 μg/ml), non-essential amino acids (NEAA), fetal bovine serum were purchased from Invitrogen (Carlsbad, CA, USA.). Transwell® inserts (12-well plates, 12 mm diameter, 1.12 cm2 surface area) with permeable polycarbonate membranes (3.0 μm pore size) were purchased from Costar (Cambridge, MA, U.S.A.). Verapamil hydrochloride, cyclosporin A, quinidine hydrochloride monohydrate, indomethacin, N-benzyl-indomethacin (NBI), acetonitrile (LC-MS Chromsolv® for HPLC), lucifer yellow CH dipotassium salt were supplied by Sigma-Aldrich (St. Louis, MO, U.S.A.).
Cell Culture
Caco-2 cells were grown in DMEM supplemented with 10% fetal bovine serum, 1% (NEAA), 1% glutamine, 5% penicillin and streptomycin in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. Caco-2 cells were used between passages 30—40. For transport experiments, 5×105 cells were seeded on polycarbonate inserts and cultured as previously described by Konsoula and Barile.25) Briefly, cells were allowed to grow and differentiate on inserts for 21—28 d. The medium was changed three times a week. The cell monolayer integrity was evaluated by measuring the transepithelial electrical resistance (TEER) with a Millicell-ERS Volt/ohmmeter (Millipore Corp., Bedford, MA, U.S.A.). TEER values greater than 400 Ω cm2 were used for the transport studies. The TEER values of the Caco-2 cell monolayer were assessed before and after the transport experiments. In addition, the flux of lucifer yellow was used as a negative control to evaluate the integrity of the monolayer.
Transport Kinetic Studies
The transport studies were performed as previously described by Konsoula and Jung.19) Briefly, the Caco-2 cell monolayers were washed twice with phosphate buffered saline (PBS) and pre-incubated for 15 min in Hanks’ balanced salt solution (HBSS) buffer (pH 7.4) at 37°C in a shaking water bath (100 rpm). Transepithelial transport was assayed by placing 150 nmol/ml of W2 either in the apical (insert) or basolateral (well) sides of Caco-2 cells. The volumes on the apical and basolateral compartments were maintained at 0.5 and 1.5 ml HBSS (pH 7.4 ), respectively. At the indicated time intervals (0, 15, 30, 60, 90, 120 min), 100 μl were withdrawn from each receiver compartment and replaced with equal volumes of HBSS buffer. The dilution was taken into consideration for the transport calculations. Appearance of W2 in the receiver side was presented as the fraction of total compound added at the beginning of the experiment. The samples were analyzed by high performance liquid chromatography (HPLC). The data points represent the mean of three independent determinations.
Transport Inhibition Studies
The inhibition of efflux of W2 across Caco-2 cells was investigated in the presence of two common P-gp inhibitors verapamil (50, 100 μm) and cyclosporin Λ (4 μm), the MRP1 inhibitors indomethacin (140 μm) and N-benzyl-indomethacin (NBI) (145 μm) as well as the mixed P-gp/MRP1 inhibitor quinidine (264 μm). The concentrations of the inhibitors were based on literature information. In addition, concentration inhibition response experiments were conducted for W2 transport in the presence of the inhibitors. The inhibitors were applied in both apical and basolateral compartments, 15 min prior to conducting the studies. During the course of the experiment, the inhibitors were present in the donor chamber with W2 as well as in the receiver chamber at the same concentrations as stated above. These experiments were conducted according to the same protocol as the transport kinetic studies. At the end of the transport experiments, the monolayer integrity was evaluated by measuring the TEER and the flux of lucifer yellow.
Apparent Permeability Coefficients (Papp)
The apparent permeability coefficient values of W2 (Papp cm/s) were evaluated from the linear part of the plot of the total amount of W2 transported by Caco-2 cell monolayers vs. time, employing the following equation26,27)
equation M1
(1)
where dC/dt (nmol/ml s) is the rate at which W2 appears in the receiver side, calculated using linear regression analysis (Microsoft Excel function), Vr is the volume in the receiver chamber (ml), Λ is the membrane surface area (cm2) and C0 is the initial concentration of W2 in the donor chamber (nmol/ml).
Efflux Ratios (ER)
Efflux ratios (ER) of W2 in the absence or presence of the inhibitors were determined from the apparent permeability coefficient values using the following equation:
equation M2
(2)
where Papp BL to AP and Papp AP to BL ratio displays the permeability values in the secretory and absorptive directions, respectively.
Chromatographic Conditions
The amount of W2 was quantified using the HPLC method as previously described by Konsoula and Jung.19) Briefly, LC was performed using a Shimadzu LC-20AD HPLC system consisting of a UV/VIS detector (SDP-20AV), degasser (DGU-20Λ), and an autosampler (SIL-HTΛ). LC was carried out on an analytical column (Phenomenex Luna C18 (2); 3.0 μm, 100 by 4.6 mm). The mobile phase consisted of acetonitrile–water with 0.1% acetic acid (50:50, v/v). The injection volume was 20 μl and the flow rate was 1 ml/min. The wavelength for detection of W2 was 330nm.
Statistical Analysis
All experiments were performed at least in triplicate. Results are presented as mean values±S.D. Statistical analysis was calculated using the Student's two-tailed unpaired t-test or one-way analysis of variance (one-way ANOVA). A value of p<0.05 was considered significant.
P-gp is a transporter which is located on the apical side of the intestinal epithelium and is responsible for the efflux of a variety of xenobiotics from the cytosol into the lumen, leading to a limited absorption and enhanced elimination of such compounds.28,29) A distinctive feature of P-gp substrates is that they demonstrate a higher transport in the excretive direction (BL to AP) compared to that in the opposite direction (AP to BL). Polarized Caco-2 cells have been described to express P-gp abundantly at the apical side.30) The results indicate that the transport of W2 across Caco-2 brush-border membranes took place in both apical to basolateral (AP to BL) and basolateral to apical (BL to AP) directions; however, the transport of W2 was asymmetric, favoring permeation in the basolateral to apical direction (Fig. 2). The Papp ratio (Papp BL to AP/Papp AP to BL) was 1.85, which suggests the involvement of an efflux transporter for W2 (Table 1). It has to be noted that a 24 h exposure of Caco-2 cell monolayers to W2 at a concentration of 150 nmol/ml had no significant effect on cell viability as determined by MTT assay (data not shown).
Fig. 2
Fig. 2
Basolateral to Apical (BL to AP) and Apical to Basolateral (AP to BL) Transport of W2 across Caco-2 Cell Monolayers
Table 1
Table 1
Comparison of the Absorptive and Secretory Coefficients (Papp) and the Efflux Ratios of W2 in the Absence or Presence of Inhibitors across Polarized Caco-2 Cell Monolayers
To investigate whether P-gp was implicated in W2 intestinal uptake, we evaluated the effect of verapamil, a well established .P-gp inhibitor.21,31) The addition of the inhibitors described below had neither a significant decrease in TEER nor a significant increase in lucifer yellow flux through the Caco-2 cell monolayers (data not shown). As illustrated in Fig. 3, verapamil inhibited the BL to AP efflux of W2 in a concentration-dependent manner. Verapamil at 50 and 100 μm significantly decreased the BL to AP efflux of W2 by 30% and 48.5% (p<0.05) respectively. Moreover, verapamil (100 μm) caused a 1.3 fold increase in the AP to BL flux of W2. The efflux ratio (ER) of W2 was determined to be equal to 1.28 and 0.73 in the presence of 50 and 100 μm verapamil respectively (Table 1), indicating that the efflux of the compound is P-gp mediated. The amount of W2 in the apical and basolateral sides was determined at the end of the transport inhibition studies. More than 90% of W2 initially used for cell exposure was recovered, suggesting that W2 was not significantly degraded or metabolized in Caco-2 cells.
Fig. 3
Fig. 3
Effect of Verapamil on the Basolateral to Apical Transport of W2
To confirm the implication of P-gp in the W2 transport on the Caco-2 cell model, 4 μm cyclosporin A32) was added to both sides of the monolayer. Cyclosporin A essentially abolished the polarized transport of W2; the Papp values of W2 significantly lowered (p<0.05) in the excretory direction (Papp BL to AP=19.7±0.2×106 cm/s) and enhanced in the absorptive direction (Papp AP to BL=19±0.3×10-6 cm/s) (Fig. 4). The difference in the transport rate of W2 in the absence and presence of cyclosporin A suggests the involvement of P-gp.
Fig. 4
Fig. 4
Effect of Cycloporin A on the Bi-directional Transport of W2
The bi-directional transport of W2 across Caco-2 cell monolayer was examined in the presence of quinidine (264 μm), a mixed inhibitor of P-gp/MRP133) (Fig. 5). Absorptive and secretory routes of W2 were compared using apparent permeability (Papp) values. According to the results, when quinidine was applied to the both sides of the monolayer, the cellular uptake of W2 from the apical side was significantly increased (Papp AP to BL 17.1±0.32×10–6 cm/s) (p<0.05) while the efflux was inhibited (Papp BL to AP 21.3±0.19×10–6 cm/s). Therefore, both W2 transports (Table 1) were sensitive to the presence of the mixed P-gp and MRP1 inhibitor.
Fig. 5
Fig. 5
Effect of Quinidine on the Bi-directional Transport of W2
Relating to the data above, we hypothesized that an additional energy carrier is involved in the W2 transport. The expression of MRP proteins on the Caco-2 cells, provides a model to study MRP-mediated transport. To explore that mechanism of transport of W2, we performed inhibitory studies with the MRP1 inhibitors23,24) indomethacin and N-benzyl-indomethacin (NBI) (Figs. 6, ,7).7). NBI treatment attenuated the basolateral to apical flux of W2 by 17.8% in Caco-2 cells, whereas this effect was completely abrogated by the presence of indomethacin (55.4% reduction) (p<0.05). Similarly, NBI significantly enhanced (p<0.05) the influx permeability of W2 (Papp AP to BL 21.7±0.11×10–6 cm/s) whereas indomethacin resulted in a moderate increase (Papp AP to BL 14.3±0.18×10–6 cm/s) (p>0.05) (Table 1). These findings suggest that MRP might play a role in limiting the oral absorption of W2.
Fig. 6
Fig. 6
Effect of Indomethacin on the Bi-directional Transport of W2
Fig. 7
Fig. 7
Effect of N-Benzyl-indomethacin (NBI) on the Bi-directional Transport of W2
Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers. The mercaptoacetamidc end moiety of HDACIs has been shown to be a good replacement of the hydroxamic acid; since zinc ion is highly thiophilic, thiol derivatives might inhibit HDAC activity by forming a covalent disulfide bond with the cysteine residues of the zinc dependent enzyme.34) Previously, we have demonstrated that the mercaptoacctamide-based HDAC inhibitor (W2) is associated with good physicochemical properties, favorable pharmacokinetics and long in vitro plasma half lives.19)
Oral anticancer chemotherapy is becoming an accepted and standard treatment of cancer, due to several advantages including convenience, reduced financial cost, and prolonged exposure to cytotoxic agents.35) However, to obtain maximum efficacy and minimum toxicity, appropriate intestinal absorption of oral anti-cancer agents is required.36) Therefore, to better understand the oral pharmacokinetic properties of the mercaptoacetamide-based HDAC inhibitor (W2), it is important to elucidate its intestinal absorption.
P-gp has been reported to alter the pharmacokinetics of numerous structurally and pharmacologically diverse drugs including anthracyclins, vinca alkaloids, podophyllotoxins and taxanes.28,29) The present study provides a line of evidence indicating an important role tor the transport proteins, and in particular P-gp, in the disposition of the mercaptoacetamide-based HDAC inhibitor. According to the data (Fig. 2), W2 exhibited asymmetric transport as indicated by 1.85 fold higher excretive (Papp=24.7±0.12×10–6 cm/s) than absorptive (Papp=13.3±0.2×10–6 cm/s) flux. However, the presence of the P-gp inhibitor (100 μm verapamil) reduced markedly the secretory permeation (Papp=12.7±22×10–6 cm/s) of W2 and increased significantly the absorptive transport (Papp=17.3±0.12×10–6 cm/s) across the Caco-2 cell monolayer (Fig. 3). Further confirmation of the results was obtained by performing inhibition studies with cyclosporin A. This P-gp inhibitor significantly inhibited the polarized efflux of W2, i.e. the efflux ratio Papp BL to AP/Papp AP to BL decreased from 1.85 to 1.03 (Table 1). These results imply that P-gp might limit the oral bioavailability of W2 by transporting absorbed drug back into the lumen. Recent evidence indicates that in the intestine, P-gp inhibition30) by co-administered compounds can increase the absorption of its substrate drugs and several clinically important interactions of this type have been documented.37,38)
Clearly, to modulate resistance to cancer chemotherapy, a more comprehensive understanding of the interactions between efflux transporters and chemotherapeutic agents is required. The findings of our study revealed that the polarized transport of W2 was competitively inhibited by quinidne (Fig. 5), a mixed inhibitor of P-gp and MRP, suggesting involvement of multiple carriers in the efflux transport of W2. MRP is another protein associated with drug resistance, which could be another possible efflux protein decreasing absorption at the intestinallevel.39) The overlapping phenotypes mediated by P-gp and MRP1 suggests the possibility of W2 being an MRP1 substrate.40) As shown by the apparent permeability coefficient values (Table 1), marked differences were observed between the secretion of W2 alone and in the presence of the MRP inhibitors. Indomethacin and NBI lowered the efflux ratio of W2 to 0.77 and 0.93 (Table 1), respectively, indicating the involvement of MRP1. Employing the Caco-2 cell line as a model of the intestinal mucosa, this is the first study that provides insight into the role and importance of the transporters in the disposition of the mercaptoacetamide-based HDAC inhibitor. However, due to the complex transport system, future studies using P-gp or MRP over-expressing cells should elucidate the individual role of each transporter in this process.
In summary, our findings provide initial evidence that the absorption and secretion of W2 are mediated by carrier mediated transport systems, including P-gp and MRP1. Therefore, the absorption of W2 could be enhanced by administered together with P-gp/MRP inhibitors. Further studies are required to elucidate other transport mechanisms involved in W2 transport as well as to explore Lhe mechanism for the pharmacokinetic W2-drug interaction and ultimately, develop clinical strategies to overcome resistance.
Acknowledgements
We thank Gene therapy pharmaceuticals for providing the compounds. This work was supported by the grant, P02 CA74175 (to A.D. and M.J.) from the National cancer Institute.
1. Acharya MR, Sparreboom A, Venitz J, Figg WD. Mol. Pharm. 2005;68:917–932. [PubMed]
2. Karagiannis TC, El-Osta A. Cell Cycle. 2006;5:288–295. [PubMed]
3. Minucci S, Pelicci PG. Nat. Rev. Cancer. 2006;6:38–51. [PubMed]
4. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. Cancer Res. 2001;61:8492–8497. [PubMed]
5. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. J. Clin. Oncol. 2005;23:3912–3922. [PubMed]
6. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen T, Grochow LB, Donehower RC. Clin. Cancer Res. 2001;7:3047–3055. [PubMed]
7. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR. Blood. 2005;105:959–967. [PubMed]
8. Takano M, Yumoto R, Murakami T. Pharmacol. Ther. 2006;109:137–161. [PubMed]
9. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH. J. Pharmacol. Exp. Ther. 2004;311:476–484. [PubMed]
10. Artursson P, Palm K, Luthman K. Adv. Drug Deliv. Rev. 2001;46:27–43. [PubMed]
11. Brunet JL, Maresca M, Fantini J, Belzunces LP. Toxicol. Appl. Pharmacol. 2004;194:1–9. [PubMed]
12. Zhou SF, Li Y, Kestell P, Schafer E, Chan E, Paxton JW. Eur. J Drug Metab. Pharmacokinet. 2005;30:49–61. [PubMed]
13. Hidalgo IJ, Raub TJ, Borchardt RT. Gastroenterology. 1989;96:736–749. [PubMed]
14. Delie F, Rubas W. Crit. Rev. Ther. Drug Carrier Syst. 1997;14:221–286. [PubMed]
15. Maeng HJ, Yoo HJ, Kim IW, Song IS, Chung SJ, Shim CK. J. Pharm. Sci. 2002;91:2614–2621. [PubMed]
16. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. J. Biol. Chem. 1993;268:14991–14997. [PubMed]
17. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn Langguth H, Wunderli Allenspach H, Merkle HP, Langguth P. J. Pharm. Sci. 1998;87:757–762. [PubMed]
18. Chen B, Petukhov PA, Jung M, Velena A, Eliseeva E, Drilschilo A, Kozikowski AP. Bioorg. Med. Chem. Lett. 2005;15:1389–1392. [PubMed]
19. Konsoula R, Jung M. Int. J. Pharm. 2008;361:19–25. [PMC free article] [PubMed]
20. Leslie EM, Deeley RG, Cole SPC. Toxicol. Appl. Pharmacol. 2005;204:216–237. [PubMed]
21. Sandstrom R, Karlsson A, Lennernas H. J. Pharm. Pharmacol. 1988;50:729–735. [PubMed]
22. Cao J, Murase O, Schowen RL, Aube J, Borchardt RT. Pharm. Res. 2001;18:171–176. [PubMed]
23. Maguire AR, Plunkett SJ, Papot S, Clynes M, O'Connor R, Touhey S. Bioorg. Med. Chem. 2001;9:745–762. [PubMed]
24. Rosenbaum C, Röhrs S, Müller O, Waldmann H. J. Med. Chem. 2005;48:1179–1187. [PubMed]
25. Konsoula R, Barile F. Toxicolngy in Vitro. 2005;19:675–684. [PubMed]
26. Artursson P, Karlson J. Biochem. Biophys. Res. Commun. 1991;175:880–885. [PubMed]
27. Meaney C, O'Driscoll C. Eur. J. Pharm. Sci. 1999;8:167–175. [PubMed]
28. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. J. Pharmacol. Exp. Ther. 2001;299:620–628. [PubMed]
29. Benet L, Cummins C, Wu C. Curr. Drug Metab. 2003;4:393–398. [PubMed]
30. Matheny C, Lamb M, Brouwer K, Pollak G. Pharmacotherapy. 2001;21:778–796. [PubMed]
31. Perloff MD, Stormer E, von Moltke LL, Greenblatt DJ. Pharm. Res. 2003;20:1177–1183. [PubMed]
32. Carrero JC, Lugo H, Pérez DG, Ortiz-Martínez C, Laclette JP. Int. J. Pharm. 2004;34:1091–1097. [PubMed]
33. Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL. J. Pharmacol. Exper. Ther. 2001;298:1199–1205. [PubMed]
34. Snzuki T, Matsura A, Kouketsu A, Nakagawa H, Miyata N. Bioorg. Med. Chem. Lett. 2005;15:331–335. [PubMed]
35. DeMario MD, Ratain MJ. J. Clin. Oncol. 1998;16:2557–2567. [PubMed]
36. Terwogt JMM, Schellens JHM, Huinink WWT, Beijnen JH. Cancer Treat. Rev. 1999;25:83–101. [PubMed]
37. Adachi Y, Suzuki H, Sugiyama Y. Pharm. Res. 2001;18:1660–1668. [PubMed]
38. Aszalos A. Arch. Pharm. Res. 2004;27:127–135. [PubMed]
39. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K. J. Bioenerg. Biomembr. 2001;33:493–501. [PubMed]
40. van Zuylen L, Nooter K, Sparreboom A, Verweij J. Investig. New Drugs. 2000;18:205–220. [PubMed]